Diagnosis and management of complex diseases requires sophisticated diagnostic assays performed in specialized laboratories. To come to a more personalized approach new, cost effective, strategies need to be developed for patients or caregivers outside specialized laboratories.
Enzyre has realized proof of concept to measure enzymatic reactions in a small volume of blood based on chemiluminescence. Due to the chemiluminescent design, no light source is required which makes the design cheap, simple, small and applicable as a real point of care device. Our strategy is to develop a multichannel device able to measure multiple existing and novel parameters supporting better disease management.
Point of Care diagnostic tools are the future in current disease management and help to individualize personalized healthcare/medicine. Our primary focus is coagulation as the clotting cascade is a waterfall of enzymatic reactions. Our point of care device will revolutionize the understanding, diagnosis and management of thrombotic and hemostatic disorders. The total market size for coagulation is estimated at €950M per year.
Three business cases have been identified for the device: hemophilia treatment management, hemodynamic monitoring in the operation room, intensive care unit and emergency and oral anti-coagulant monitoring.
Our platform is unique as it is cheap, requires just a small volume of blood and is able to measure up to 12 enzymatic reactions simultaneously with high sensitivity/specificity in a point of care setting; at home, near the patient (bedside) and even in area without any laboratory infrastructure.